Take the Quiz
Clinical Reference · Updated October 16, 2026

Dosing & Pharmacology

Wegovy: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly. Ozempic: 0.25 → 0.5 → 1.0 → 2.0 mg weekly. Rybelsus: 3 → 7 → 14 mg daily oral.

Clinical referenceUpdated October 16, 2026
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated October 16, 2026

Overview

Wegovy: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly. Ozempic: 0.25 → 0.5 → 1.0 → 2.0 mg weekly. Rybelsus: 3 → 7 → 14 mg daily oral.

Related clinical pages

Questions readers ask

How fast is Wegovy increased to the 2.4 mg dose?

Wegovy steps from 0.25 to 0.5, 1.0, 1.7 and then 2.4 mg once weekly, with roughly four weeks at each step. That means most people reach the 2.4 mg maintenance dose after about 16 weeks of titration.

Why can semaglutide injections be given only once a week?

Semaglutide has a half-life of about 7 days, so a single subcutaneous injection keeps working through the week. The injection goes into the abdomen, thigh or upper arm, while oral Rybelsus is taken daily instead.

How does Ozempic dosing differ from Wegovy dosing?

Ozempic, used for type 2 diabetes, runs 0.25, 0.5, 1.0 and 2.0 mg weekly, so its maximum is 2.0 mg. Wegovy, used for weight management, adds a 1.7 mg step and tops out at 2.4 mg weekly.

What are the Rybelsus tablet doses?

Rybelsus is oral semaglutide taken once daily, stepping from 3 mg to 7 mg and then 14 mg. It is approved for type 2 diabetes and uses an absorption enhancer so the peptide can be taken by mouth.

Primary sources

  1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  2. FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
  3. FDA: Compounding and the FDA — questions and answers
  4. FDA: Registered outsourcing facilities (503B)
  5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
  6. Wegovy (semaglutide) prescribing information, Novo Nordisk